Clinical Trial Update: Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu)Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for extended intraputaminal infusion of Liatermin (r-metHuGDNF) in idiopathic Parkinson's disease patients who completed a prior Liatermin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Liatermin (r-metHuGDNF)

Snippet

Sponsor: Amgen | Conditions: Parkinson's Disease | Phase 1, Phase 2 | Status: COMPLETED